Collagen Solutions (COS) investor presentation 26.2.18
CEO Jamal Rushdy and new CFO Hilary Spence present a business overview and an update of the ChondroMimetic® clinical study.
http://www.piworld.co.uk/2018/03/01/collagen-solutions-cos-investor-presentation-26th-february-2018/
Jamal Rushdy CEO introduction – 00:18
Regenerative medicine overview – 01:12
What Collagen Solutions does – 2:40
Core business model – 5:53
Revenue trend – 9:39
ChondroMimetic® introduction – 10:21
Knee cartilage disease progression – 12:28
Current treatments – 14:55
ChondroMimetic® clinical study – 17:35
Study highlights – 18:31
Study data introduction – 22:16
Study results – 23:51
Market opportunities – 28:03
Key competitive differentiators – 31:55
Conclusions & next steps – 33:30
Q&A – 35:25
Other uses of ChondroMimetic®? – 35:26
US Regulation? – 37:10
How long does the treatment last? – 39:47
Other geographical markets? – 41:28
Partnerships? – 42:34
Cashflow – 44:50
End – 46:42
Rosen's Diversified Inc Recommended Cash Offer for Collagen Solutions plc
Under the terms of the Offer, Collagen Shareholders will be entitled to receive 6.5 pence in cash for each Collagen Share held, valuing the entire existing issued and to be issued ordinary share capital of Collagen, including the existing shareholding of RDI, at approximately GBP 30.41 million on a fully diluted basis.
Not a bad outcome.
BSV
